These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36804489)

  • 1. A pilot randomized controlled trial of ketamine in Borderline Personality Disorder.
    Fineberg SK; Choi EY; Shapiro-Thompson R; Dhaliwal K; Neustadter E; Sakheim M; Null K; Trujillo-Diaz D; Rondeau J; Pittaro GF; Peters JR; Corlett PR; Krystal JH
    Neuropsychopharmacology; 2023 Jun; 48(7):991-999. PubMed ID: 36804489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial.
    Grunebaum MF; Galfalvy HC; Choo TH; Keilp JG; Moitra VK; Parris MS; Marver JE; Burke AK; Milak MS; Sublette ME; Oquendo MA; Mann JJ
    Am J Psychiatry; 2018 Apr; 175(4):327-335. PubMed ID: 29202655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation.
    Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Mao WC; Tu PC; Chen LF; Li WC; Chen MH
    Int J Neuropsychopharmacol; 2023 May; 26(5):331-339. PubMed ID: 36966411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
    Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
    Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute Dissociation and Ketamine's Antidepressant and Anti-Suicidal Ideation Effects in a Midazolam-Controlled Trial.
    Sajid S; Galfalvy HC; Keilp JG; Burke AK; Mann JJ; Grunebaum MF
    Int J Neuropsychopharmacol; 2024 Apr; 27(4):. PubMed ID: 38573154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Right dorsolateral prefrontal cortex volumetric reduction is associated with antidepressant effect of low-dose ketamine infusion: A randomized, double-blind, midazolam-controlled PET-MRI clinical trial.
    Li WC; Chen LF; Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Tu PC; Chen MH
    J Affect Disord; 2023 Aug; 335():105-110. PubMed ID: 37178823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.
    Feder A; Costi S; Rutter SB; Collins AB; Govindarajulu U; Jha MK; Horn SR; Kautz M; Corniquel M; Collins KA; Bevilacqua L; Glasgow AM; Brallier J; Pietrzak RH; Murrough JW; Charney DS
    Am J Psychiatry; 2021 Feb; 178(2):193-202. PubMed ID: 33397139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial.
    Grunebaum MF; Ellis SP; Keilp JG; Moitra VK; Cooper TB; Marver JE; Burke AK; Milak MS; Sublette ME; Oquendo MA; Mann JJ
    Bipolar Disord; 2017 May; 19(3):176-183. PubMed ID: 28452409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketamine metabolite pilot study in a suicidal depression trial.
    Grunebaum MF; Galfalvy HC; Choo TH; Parris MS; Burke AK; Suckow RF; Cooper TB; Mann JJ
    J Psychiatr Res; 2019 Oct; 117():129-134. PubMed ID: 31415914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder.
    Danayan K; Chisamore N; Rodrigues NB; Vincenzo JDD; Meshkat S; Doyle Z; Mansur R; Phan L; Fancy F; Chau E; Tabassum A; Kratiuk K; Arekapudi A; Teopiz KM; McIntyre RS; Rosenblat JD
    Psychiatry Res; 2023 May; 323():115133. PubMed ID: 36889160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological interventions for people with borderline personality disorder.
    Stoffers-Winterling JM; Storebø OJ; Pereira Ribeiro J; Kongerslev MT; Völlm BA; Mattivi JT; Faltinsen E; Todorovac A; Jørgensen MS; Callesen HE; Sales CP; Schaug JP; Simonsen E; Lieb K
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD012956. PubMed ID: 36375174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression.
    Lineham A; Avila-Quintero VJ; Bloch MH; Dwyer J
    J Child Adolesc Psychopharmacol; 2023 Feb; 33(1):20-26. PubMed ID: 36799961
    [No Abstract]   [Full Text] [Related]  

  • 13. Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression.
    Hochschild A; Keilp JG; Madden SP; Burke AK; Mann JJ; Grunebaum MF
    J Affect Disord; 2022 Mar; 300():10-16. PubMed ID: 34953926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Ketamine Versus Midazolam on Neurocognition at 24 Hours in Depressed Patients With Suicidal Ideation.
    Keilp JG; Madden SP; Marver JE; Frawley A; Burke AK; Herzallah MM; Gluck M; Mann JJ; Grunebaum MF
    J Clin Psychiatry; 2021 Nov; 82(6):. PubMed ID: 34727422
    [No Abstract]   [Full Text] [Related]  

  • 15. Lamotrigine for people with borderline personality disorder: a RCT.
    Crawford MJ; Sanatinia R; Barrett B; Cunningham G; Dale O; Ganguli P; Lawrence-Smith G; Leeson VC; Lemonsky F; Lykomitrou-Matthews G; Montgomery A; Morriss R; Munjiza J; Paton C; Skorodzien I; Singh V; Tan W; Tyrer P; Reilly JG
    Health Technol Assess; 2018 Apr; 22(17):1-68. PubMed ID: 29651981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study protocol for Ketamine as an adjunctive therapy for major depression (2): a randomised controlled trial (KARMA-Dep [2]).
    Jelovac A; McCaffrey C; Terao M; Shanahan E; Mohamed E; Whooley E; McDonagh K; McDonogh S; Igoe A; Loughran O; Shackleton E; O'Neill C; McLoughlin DM
    BMC Psychiatry; 2023 Nov; 23(1):850. PubMed ID: 37974160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.
    Ionescu DF; Bentley KH; Eikermann M; Taylor N; Akeju O; Swee MB; Pavone KJ; Petrie SR; Dording C; Mischoulon D; Alpert JE; Brown EN; Baer L; Nock MK; Fava M; Cusin C
    J Affect Disord; 2019 Jan; 243():516-524. PubMed ID: 30286416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short term ketamine treatment in patient with bipolar disorder with comorbidity with borderline personality disorder: Focus on impulsivity.
    Gałuszko-Węgielnik M; Jakuszkowiak-Wojten K; Wilkowska A; Cubała WJ
    World J Biol Psychiatry; 2023 Nov; 24(9):849-853. PubMed ID: 37338035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
    Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
    Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial.
    Fan W; Yang H; Sun Y; Zhang J; Li G; Zheng Y; Liu Y
    Oncotarget; 2017 Jan; 8(2):2356-2360. PubMed ID: 27926528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.